Development of prediction model for alanine transaminase elevations during the first 6 months of conventional synthetic DMARD treatment

Frequent laboratory monitoring is recommended for early identification of toxicity when initiating conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). We aimed at developing a risk prediction model to individualize laboratory testing at csDMARD initiation. We identified inflamma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuusalo, Laura, Venäläinen, Mikko S., Kirjala, Heidi, Saranpää, Sofia, Elo, Laura L., Pirilä, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412531/
https://www.ncbi.nlm.nih.gov/pubmed/37558753
http://dx.doi.org/10.1038/s41598-023-39694-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412531/
https://www.ncbi.nlm.nih.gov/pubmed/37558753
http://dx.doi.org/10.1038/s41598-023-39694-2

Ejemplares similares